Long-Term Gantenerumab May Slow Decline in Dominantly Inherited Alzheimer Disease

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on March 25, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, March 25, 2025 -- For individuals with dominantly inherited Alzheimer disease (DIAD), long-term treatment with gantenerumab, an anti-amyloid beta antibody, may delay clinical decline, according to a study published in the April issue of The Lancet Neurology.

Randall J. Bateman, M.D., from Washington University School of Medicine in St. Louis, and colleagues conducted a three-year open-label extension (OLE) study to examine the safety and efficacy of long-term treatment with high-dose gantenerumab. The study was conducted at 18 sites and enrolled 73 individuals at risk for DIAD, who had participated in a phase 2/3 multiarm trial (DIAN-TU-001) and had known mutation status. The study was stopped early after a prespecified interim analysis due to lack of a regulatory path for gantenerumab. The primary outcome for the final analysis was the amyloid plaque measure ¹¹C-Pittsburgh compound-B positron emission tomography (PiB-PET) standardized uptake value ratio (SUVR [PiB-PET SUVR]) assessed in the modified intention-to-treat group at three years.

The researchers found that 47 participants stopped dosing due to early study termination and 13 discontinued prematurely for other reasons. At the interim analysis, in asymptomatic mutation carriers, the hazard ratio for clinical decline in the Clinical Dementia Rating-Sum of Boxes was 0.79 for participants treated with gantenerumab in either the double-blind or OLE period (95 percent confidence interval, 0.47 to 1.32) and 0.53 for those treated with gantenerumab the longest (95 percent confidence interval, 0.27 to 1.03). The adjusted mean change from OLE baseline to year 3 in PiB-PET SUVR was −0.71 SUVR at the final analysis.

"I am highly optimistic now, as this could be the first clinical evidence of what will become preventions for people at risk for Alzheimer's disease," Bateman said in a statement.

Several authors disclosed ties to biopharmaceutical companies, including F. Hoffmann-La Roche/Genentech, which is developing gantenerumab.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-03-26 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords